Michael J Carr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/590273/publications.pdf

Version: 2024-02-01

1307594 1199594 21 177 7 12 citations g-index h-index papers 21 21 21 229 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	In-transit metastatic cutaneous melanoma: current management and future directions. Clinical and Experimental Metastasis, 2022, 39, 201-211.	3.3	6
2	Sentinel lymph node biopsy in melanoma: beyond histologic factors. Clinical and Experimental Metastasis, 2022, 39, 29-38.	3.3	11
3	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Annals of Surgical Oncology, 2022, 29, 791-801.	1.5	18
4	External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. Annals of Surgical Oncology, 2022, 29, 1637-1644.	1.5	5
5	ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. Annals of Surgical Oncology, 2022, 29, 1647.	1.5	O
6	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
7	Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. Clinical Breast Cancer, 2021, 21, e189-e193.	2.4	18
8	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. Journal of the American College of Surgeons, 2021, 232, 424-431.	0.5	14
9	Molecular Aspects of the Isolated Limb Infusion Procedure. Biomedicines, 2021, 9, 163.	3.2	3
10	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 6995-7003.	1.5	8
11	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.7	3
12	ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy. Annals of Surgical Oncology, 2021, 29, 802.	1.5	0
13	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. Annals of Surgical Oncology, 2021, 29, 804.	1.5	3
14	Principles of Targeted Therapy for Melanoma. Surgical Clinics of North America, 2020, 100, 175-188.	1.5	40
15	An evaluation of encorafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2020, 21, 155-161.	1.8	11
16	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World Journal of Surgery, 2020, 44, 1283-1293.	1.6	8
17	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. Expert Review of Anticancer Therapy, 2020, 20, 687-701.	2.4	6
18	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International ComparisonÂof the Procedure and Outcomes Between the United States and Australia. Annals of Surgical Oncology, 2020, 27, 5107-5118.	1.5	8

MICHAEL J CARR

#	Article	IF	CITATIONS
19	ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. Annals of Surgical Oncology, 2020, 27, 5119-5120.	1.5	1
20	Isolated limb infusion: Institutional protocol and implementation. Journal of Surgical Oncology, 2020, 122, 99-105.	1.7	7
21	Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Cancer Control, 2020, 27, 107327482098301.	1.8	7